Sonoma Pharmaceuticals, Inc. (SNOA) earnings
SNOA earnings moved a median of -1.02% by the close. Quarterly and annual SNOA reports and results, each read against the price at its own news timestamp. Back to the SNOA overview →
15 measured SNOA earnings events.
Where these SNOA earnings landedvs 15 measured SNOA earnings reactions
| Middle 50% of SNOA earnings reactions | -5.00% to +0.53% |
|---|---|
| Median reaction (to close) | -1.02% |
| Measured reactions | 15 |
Point-in-time · zero look-ahead
Half of the 15 SNOA earnings events with a measured close landed between -5.00% and +0.53%; 27% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Sonoma Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | +0.00% | +0.00% | |
| Form 10-K Sonoma Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-K | -1.89% | +8.49% | |
| Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results | Press release | -1.89% | +8.49% | |
| Form 10-Q Sonoma Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-Q | +0.00% | +1.06% | |
| Form 10-Q Sonoma Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | -1.06% | -0.53% | |
| Form 10-Q Sonoma Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | -3.53% | -1.92% | |
| Form 10-K Sonoma Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-K | +0.33% | -5.00% | |
| Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2025 Financial Results | Press release | +0.33% | -5.00% | |
| Form 10-Q Sonoma Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-Q | +0.00% | -0.38% | |
| Form 10-Q Sonoma Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -1.02% | |
| Form 10-Q Sonoma Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | -2.49% | -14.37% | |
| Form 10-K Sonoma Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-K | +9.62% | -26.15% | |
| Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2024 Financial Results | Press release | +9.62% | -26.15% | |
| Form 10-Q Sonoma Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-Q | -1.47% | -2.39% | |
| Form 10-Q Sonoma Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | +6.11% | +2.23% |
Keep exploring
More SNOA: analyst actions → · SEC filings → · SNOA overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Iterum Therapeutics plc - Ordinary Share (ITRM) | 168 | 0.00% | 49% |
| BIOSTAR PHARMS INC (BSPM) | 167 | 0.00% | 41% |
| Boundless Bio, Inc. (BOLD) | 166 | -0.48% | 44% |
| CymaBay Therapeutics Inc. (CBAY) | 166 | +0.02% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.